The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

The best metric is not weight, but a particularly toxic kind of fat.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Health-care companies rose sharply after President Trump signed an executive order designed to lower what Americans pay for prescription drugs that offered pharmaceutical companies room for ...